CDX Regulatory News

PFAS: ECHA Committees Reach Conclusions on First Sectors

July 22, 2025

The European Chemicals Agency's (ECHA) scientific committees made progress on the EU-wide proposal to restrict per- and polyfluoroalkyl substances (PFAS) during their June 2025 meetings.

The Committee for Risk Assessment (RAC) and the Committee for Socio-Economic Analysis (SEAC) continued their detailed evaluation of the proposal, reaching provisional conclusions for several key sectors:

  • Both committees reached provisional conclusions regarding the use of PFAS in medical devices.
  • RAC also reached provisional conclusions for lubricants.
  • SEAC reached provisional conclusions for the transport sector.

The committees also announced a tentative plan for which sectors will be evaluated next. The upcoming schedule includes:

  • September 2025: Topics will include electronics, semiconductors, PFAS manufacturing, and general considerations such as enforceability and concentration limits. SEAC will also continue its work on energy and lubricants.
  • Post-September 2025: Continued evaluation of electronics, semiconductors and PFAS manufacturing.

Identify PFAS risks in your supply chain

Thousands of PFAS substances face restrictions globally, and regulations change fast. CDX maps your product portfolio for PFAS exposure, analyzes concentration levels, and flags compliance gaps before they become costly problems.

Learn how CDX helps with PFAS compliance

Other News You May Be Interested In
 

EU proposes harmonised end-of-waste criteria for recycled plastic
August 10, 2026
EU proposes harmonised end-of-waste criteria for recycled plastic
Japan's PFHxS restriction enters into force, confirming import ban on treated products
August 10, 2026
Japan's PFHxS restriction enters into force, confirming import ban on treated products
UK explores its own Digital Product Passport record policy
August 10, 2026
UK explores its own Digital Product Passport (DPP) record policy, with call for evidence open until September

Stay informed. Get the latest regulatory updates, compliance insights, and CDX news delivered to your inbox.

Subscribe to our Newsletter